Table 3.

Agreement between clinical and [¹⁸F]FDG PET diagnoses

	Disclosure of amyloid PET results		Change (%)
	Before	After
All patients (n = 84)	62 (kappa = 0.24)*	86 (kappa = 0.71)**	24% (chi2 = 13.9)**
Early onset (≤65 years; n = 36)	64 (kappa = 0.25)	92 (kappa = 0.83)**	28% (chi2 = 6.8)**
Late-onset (>65 years; n = 48)	60 (kappa = 0.2)	81 (kappa = 0.63)**	21% (chi2 = 5.8)*
Early vs. late onset	n.s.	n.s. (p = 0.156)	n.s.
Late onset, AUC consistent (n = 33)	64 (kappa = 0.17)	85 (kappa = 0.69)**	21% (chi2 = 4.0)*
Late onset, not AUC consistent (n = 15)	53 (kappa = −0.13)	73 (kappa = 0.40)	20% (chi2 = 0.8)
Late onset, consistent vs. not consistent	n.s.	n.s.	n.s.

AUC Appropriate Use Criteria, n.s. not significant

**p < 0.01, *p < 0.05